Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG1205 placebo-controlled phase II study in moderate Crohn's disease
2014-001892-30Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing GLPG1205 with Placebo (2 arms). Primary endpoint: Difference in CDAI change from baseline between GLPG1205- and placebo-treated subjects at Week 12. Started Sep 2014; status: completed.
02
Drugs
GLPG1205
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-001892-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001892-30.